Specialty Pharmacy

Upadacitinib, an oral agent designed to selectively inhibit JAK1, is being studied as a once-daily therapy in rheumatoid arthritis.

Top news of the day from across the health care landscape.

I went to work for an independent pharmacist, some 43 years ago, for the chance to learn something about the profession of pharmacy. The profession has changed so much from the original journey I envisioned.

Officials with the FDA granted orphan drug designation for Reviva Pharmaceuticals’ clinical stage drug candidate, RP5063 for treatment of idiopathic pulmonary fibrosis.

John Giannouris, vice president, Specialty Pharmacy Services, ValueCentric, discusses the data customers should be asking for from a specialty pharmacy.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Community pharmacists urge Congress to support 3 priority bills that create transparency for pharmacy benefit managers and improve patient access.

Top news of the day from across the health care landscape.

The EGFR/TNF inhibitor treatment effectively blocks the tumor necrosis factor escape route for non-small cell lung cancer.

Access to diagnosis and treatment must be improved worldwide to meet target goals for the elimination of viral hepatitis.

Due to lack of data on menopause and HIV, many women living with HIV infection have limited access to medical care and support.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Julianne Orr, PharmD, from the Indiana University Health Simon Cancer Center, discusses how pharmacists can help patients who are transitioning from an infusion product to an oral chemotherapy.

Top news of the day from across the health care landscape.

US report indicates new drivers of death have emerged over time and have continued to unequally affect residents at the state level.

The therapy is a combination of a checkpoint drug, nivolumab, and a new immune stimulation drug, ALT-803.

New drug shows promising signs of delaying the development of existing breast and lung cancers. .

The triple combination includes a novel cystic fibrosis transmembrane conductance regulator amplifier, third generation corrector, and potentiator.

Pediatric patients treated with larotrectinib in a clinical trial demonstrated a 93% response rate.

An experimental program in Maryland aimed to reduce health care spending by shifting away from hospital-based care and toward less costly, primary, preventive, and outpatient services.

Top news of the day from across the health care landscape.

Upadacitinib met primary endpoints of ACR20 and clinical remission versus placebo in treatment of moderate to severe rheumatoid arthritis.

Pharmacists can help optimize medication regimens to produce the best patient outcomes at the lowest cost.

Physicians reported inaccurate self-perceptions when it came to opioid prescribing

Top news of the day from across the health care landscape.

Ron Lanton III, Esq, President, True North Political Solutions, discusses how drug manufacturers have responded to the emergence of biosimilars thus far.

Services such as Uber and Lyft that help get patients to their medical appointments could also bring patients to their pharmacies.

Rucaparib demonstrated statistically-significant improvement in progression-free survival for patients in the maintenance treatment setting.

Imraldi, a biosimilar referencing Humira, is expected to launch initially in Europe.

A novel chimera targets the growth factors responsible for certain types of breast cancer.